Question explored with the scientific record
Any cons to statins
Statins lower cholesterol, but the evidence shows they also raise your risk of muscle pain, new diabetes, and liver stress. The question is whether the trade-off is worth it for you.
The most common downside is muscle symptoms. In blinded trials, the difference between statin and placebo is tiny: about 12.7% versus 12.4% [2]. But in open-label use, where patients know what they are taking, the rate jumps to 41% or higher [4]. That gap is the nocebo effect: people feel what they expect to feel. Still, for the roughly 1 in 10 who have real muscle pain, it can be disabling. A 2025 review found that switching to a lower dose plus ezetimibe cut muscle symptom rates from 5.7% to 0.7% [1].
The second major risk is new-onset diabetes. A meta-analysis of 11 studies covering 236,864 people found statin users had about 1.6 times the odds of developing diabetes [7]. In absolute terms, that means about 8 in 100 statin users developed diabetes versus 5 in 100 non-users [6]. Higher doses increase the risk: high-intensity statins raised diabetes incidence to 7.8% versus 5.8% for moderate doses in one study [5]. The risk appears across all statins, though pitavastatin may have a lower rate [8].
Liver enzyme elevations are common but rarely serious. About 3% of long-term users show elevated ALT [3]. Severe liver injury is very rare, roughly 1 in 114,000 patient-years [10]. A 2021 case report showed that liver injury can recur when switching to a different statin, suggesting a class effect in susceptible people [9].
| Risk | Approximate rate in statin users | Comparison |
|---|---|---|
| Muscle symptoms (blinded trials) | 12.7% | vs 12.4% placebo [2] |
| Muscle symptoms (open-label) | 41% | vs 3% blinded [4] |
| New diabetes | 7.8% | vs 4.8% non-users [6] |
| Elevated liver enzymes | 3% | resolves on stopping [3] |
| Severe liver injury | ~1 in 114,000 patient-years | very rare [10] |
The cardiovascular benefit is real: about a 20% relative reduction in heart attacks and strokes per 39 mg/dL LDL drop [2]. But that benefit is largest in people who already had a heart attack or have very high LDL. For primary prevention in healthy people with moderately elevated cholesterol, the absolute benefit is small, and the diabetes risk may offset it.
My call: statins help some people, especially those with established heart disease, but the downsides are real and the evidence for primary prevention in low-risk people is weaker than advertised. Confidence: moderate.
Sources used 10
-
Diagnosis and Management of Statin-Associated Muscle Symptoms
This state-of-the-art review summarizes the pathophysiology, clinical presentation, diagnostic challenges, and management of statin-associated muscle symptoms (SAMS), emphasizing diagnostic tools (e.g., SAMS-CI, dechallenge/rechallenge) and evidence that combination statin+ezeti…
DOI: 10.4070/kcj.2025.0285 -
Statin‐associated muscle symptoms: Does the benefit outweigh the risk factor?
This editorial argues that although statin-associated muscle symptoms are common and certain risk factors exist, the overall cardiovascular benefit of statins outweighs the risk in most patients.
DOI: 10.1002/mus.26470 -
Managing statin-related side effects: should we avoid or overcome them?
Statins provide strong cardiovascular protection with a low rate of significant adverse effects; most statin-associated muscle symptoms are non-pharmacologic or nocebo-driven and can be managed with evidence-based strategies to maintain therapy.
DOI: 10.36011/cpp.2026.8.e2 -
Effects of nocebo and drusebo in determining statin-induced muscle symptoms
Nocebo and drucebo effects largely explain statin-associated muscle symptoms (SAMS), with blinded trials showing little to no difference between statin and placebo and cross-over n-of-1 studies highlighting the need for patient-centered management to preserve statin adherence.
DOI: 10.21518/2079-701x-2022-16-17-136-142 -
Different diabetogenic effect of statins according to intensity and dose in patients with acute myocardial infarction: a nationwide cohort study
This nationwide cohort study investigates the differential diabetogenic effects of statins based on their intensity and dose in patients with acute myocardial infarction, revealing that high-intensity statin therapy is associated with a higher incidence of new-onset diabetes mel…
DOI: 10.1038/s41598-024-67585-7 -
Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database
This population-based cohort study investigates the association between statin use and the risk of new onset diabetes mellitus (NODM) in patients with ischemic heart disease, revealing that statin users have a significantly higher incidence of NODM compared to non-statin users.
DOI: 10.2147/tcrm.s117150 -
Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis
A meta-analysis of 11 studies (236,864 subjects) found statin use was associated with a small but statistically significant increased risk of new-onset diabetes mellitus (fixed-effects OR 1.61, 95% CI 1.55-1.68; p < 0.001).
DOI: 10.1159/000485196 -
Effect of Pitavastatin Compared with Atorvastatin andRosuvastatin on New-Onset Diabetes Mellitus in PatientsWith Acute Myocardial Infarction
This study investigates the impact of moderate-intensity pitavastatin compared to atorvastatin and rosuvastatin on the incidence of new-onset diabetes mellitus in patients with acute myocardial infarction, finding that pitavastatin is associated with a significantly lower incide…
DOI: 10.1016/j.amjcard.2018.06.017 -
A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect?
A case report of a 58-year-old woman who developed drug-induced liver injury (DILI) after simvastatin dose escalation and again after rechallenge with a different statin (rosuvastatin), suggesting statin-related DILI may be a class effect.
DOI: 10.1515/jbcpp-2021-0013 -
Adverse effects of statin therapy and their treatment
A narrative review summarizing the adverse effects of statin therapy (hepatic dysfunction, myopathy, and diabetes risk) and their management, comparing major international guidelines and offering practical recommendations.
DOI: 10.36011/cpp.2022.4.e4